Roche opens €90m gene therapy development centre
Roche sees the €90m investment as a harbinger of the German government's "National Strategy for Gene and Cell Therapies", which has been...
Biovian and 3P Biopharmaceuticals join forces to create 3PBIOVIAN
Finnish Biovian Oy and Pamplona-based 3P Biopharmaceuticals Srl have joined forces to build a pan-European Contract Development and Manufacturing...
Shock: Adrenomed AG gets FDA fast track designation
After Adrenomed AG has demonstrated that its septic shock treatment led to a 60% reduction in relative 28-day mortality vs. placebo in a stratified...
Deregulation of new genomic techniques before decision
Although the required approval of 15 agriculture ministers was achieved in mid-December, the hotly debated proposal of the EU Commission to relax...
Bayer's Ask Bio unit starts Phase II heart failure gene therapy
The Phase II trial called GenePHIT is the largest adaptive, double-blind, placebo-controlled, randomised, multicentre trial ever to evaluate the...
Novo Nordisk to acquire Cardior Pharmaceuticals
The take-over agreement includes Cardior’s lead compound CDR132L, currently in Phase II clinical development for the treatment of heart failure....
Solar Foods starts Factory01
Following market authorisation in Singapore two years ago, the Finnish company Solar Foods Oy and the Japanese food giant Ajinomoto Group want to...